Erlotinib (Tarceva) experience in a public health system, minority patient population with progressive metastatic non-small cell lung cancer (mNSCLC)

被引：0
|
作者：
Nathan, Sunita [1 ]
Patel, Pritesh [1 ]
Sharma, Jennifer [1 ]
Samuel, Joyce [1 ]
Stroger, John H., Jr. [1 ]
机构：
[1] Cook Cty Hosp, Chicago, IL USA
来源：
CHEST | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：588S / 589S
页数：2
相关论文
共 50 条
  • [21] COST OF IMMUNOTHERAPY TO TREAT LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (MUC) AND METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC)
    Bilir, S. P.
    Munakata, J.
    Yim, Y. M.
    Ogale, S.
    VALUE IN HEALTH, 2017, 20 (05) : A99 - A99
  • [22] Statins (ASIs) may improve the outcome of erlotinib as second line treatment (tx) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
    Maimon, Natalie
    Keizman, Daniel
    Gottfried, Maya
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Experience of erlotinib for non-small cell lung cancer (NSCLC) at the Exeter Oncology Centre
    Minear, F. G.
    Ward, A. J.
    Dorey, N. E.
    Osborne, M. E.
    Toy, E. W.
    LUNG CANCER, 2011, 71 : S8 - S8
  • [24] Erlotinib and docetaxel in relapsed non-small cell lung cancer: a single centre experience
    Hook, J.
    MacDermott, C.
    Cheeseman, S.
    LUNG CANCER, 2009, 63 : S8 - S8
  • [25] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [26] Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer
    Aren, Osvaldo
    Samtani, Suraj
    Frelinghuysen, Micahel
    Burotto, Mauricio
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (04) : E375 - E379
  • [27] Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer
    Emoto-Yamamoto, Y.
    Iida, S.
    Kawanishi, T.
    Fukuoka, M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (02) : 232 - 239
  • [28] Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
    Cheon, Yun-Hong
    Kim, Moon Jin
    Kang, Min Gyu
    Kim, Hee Jin
    Lee, Sang Su
    Kim, Cha Young
    Jeon, Dae-Hong
    Kim, Yu Eun
    Lee, Gyeong-Won
    YONSEI MEDICAL JOURNAL, 2011, 52 (04) : 695 - 698
  • [29] Use of pemetrexed for non-small cell lung cancer in the Andalusian public health system
    Antonia Perez-Moreno, Maria
    Cotrina-Luque, Jesus
    Galvan-Banqueri, Mercedes
    Flores-Moreno, Sandra
    Javier Bautista-Paloma, Francisco
    Angel Calleja-Hernandez, Miguel
    JOURNAL OF CHEMOTHERAPY, 2015, 27 (06) : 371 - 377
  • [30] Erlotinib for the treatment of relapsed non-small cell lung cancer
    McLeod, C.
    Bagust, A.
    Boland, A.
    Hockenhull, J.
    Dundar, Y.
    Proudlove, C.
    Davis, H.
    Green, J.
    Macbeth, F.
    Stevenson, J.
    Walley, T.
    Dickson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 41 - 47
12345